25 June 2020 - The positive opinion marks an important milestone as the Company prepares its transformation into a commercial stage biopharmaceutical company.

Hansa Biopharma today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending conditional approval of Idefirix (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. 

Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020.

Read Hansa Medical press release